<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00723359</url>
  </required_header>
  <id_info>
    <org_study_id>969</org_study_id>
    <nct_id>NCT00723359</nct_id>
  </id_info>
  <brief_title>Safety and Dose Determining Study of BT062 in Patients With Relapsed or Refractory Multiple Myeloma</brief_title>
  <official_title>A Phase I Dose Escalation Study to Evaluate Maximum Tolerated Dose (MTD), Pharmacokinetics (PK), and Safety of BT062 in Subjects With Relapsed or Relapsed/Refractory Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biotest Pharmaceuticals Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Biotest</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Biotest Pharmaceuticals Corporation</source>
  <brief_summary>
    <textblock>
      This Phase I research study is to test the effects (good and bad) and best dose of BT062 in&#xD;
      treating patients with relapsed or refractory multiple myeloma.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2008</start_date>
  <completion_date type="Actual">April 2012</completion_date>
  <primary_completion_date type="Actual">April 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose limiting toxicity</measure>
    <time_frame>On a weekly basis for the duration of the study</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum tolerated dose</measure>
    <time_frame>About every 2 months for the duration of the study</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Qualitative and quantitative toxicities</measure>
    <time_frame>On a weekly basis for the duration of the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics</measure>
    <time_frame>On a weekly basis for the duration of the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-tumor activity</measure>
    <time_frame>At the beginning of each treatment cycle</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>BT062</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BT062 single agent dose escalation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BT062</intervention_name>
    <description>biologic</description>
    <arm_group_label>BT062</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of active multiple myeloma according to the International Myeloma Working&#xD;
             Group diagnostic criteria&#xD;
&#xD;
          -  Relapsed or relapsed/refractory multiple myeloma&#xD;
&#xD;
          -  Previous treatment with both an immunomodulator and a proteosome inhibitor therapy&#xD;
&#xD;
          -  Age ≥ 18 years&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status (Zubrod) ≤ 2&#xD;
&#xD;
          -  Ability to understand and willingness to sign a written informed consent document&#xD;
&#xD;
          -  Ability to adhere with the study visit schedule and other protocol procedures&#xD;
&#xD;
          -  Life expectancy of ≥ 12 weeks&#xD;
&#xD;
          -  Normal organ and marrow function&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Chemotherapy or radiotherapy within 3 weeks (6 weeks for nitrosoureas or mitomycin&#xD;
             C)prior to day 1 or those who have not recovered from AEs due to agents administered&#xD;
             more than 3 weeks earlier&#xD;
&#xD;
          -  Treatment with another investigational agent during the study or within 4 weeks before&#xD;
             day 1&#xD;
&#xD;
          -  Major surgery within 4 weeks before day 1 (this does not include placement of vascular&#xD;
             access device or tumor biopsies)&#xD;
&#xD;
          -  Antineoplastic therapy with biological agents within 2 weeks before day 1&#xD;
&#xD;
          -  HAHAs, HACAs, or HAMAs in response to previous MAb therapy&#xD;
&#xD;
          -  Previous participation in this study&#xD;
&#xD;
          -  Malignancy within 3 years before day 1, excluding treated non-melanoma skin cancer,&#xD;
             superficial bladder cancer and carcinoma in-situ of the cervix&#xD;
&#xD;
          -  Severe diseases of skin, colon, esophagus, or eye within 1 year before day 1, as&#xD;
             judged by the Investigator&#xD;
&#xD;
          -  Severe infections necessitating use of antibiotics&#xD;
&#xD;
          -  Clinically relevant active infection including active hepatitis B or C or human&#xD;
             immunodeficiency virus (HBV, HCV, or HIV) or any other concurrent disease which,in the&#xD;
             judgment of the investigator, would make the subject inappropriate for enrollment into&#xD;
             this study&#xD;
&#xD;
          -  Acute or relevant abnormalities in electrocardiogram (ECG), as judged by the&#xD;
             Investigator&#xD;
&#xD;
          -  Significant cardiac disease such as recent myocardial infarction (≤ 6 months prior to&#xD;
             day 1), unstable angina, uncontrolled congestive heart failure, uncontrolled&#xD;
             hypertension, (recurrent or persistent increases in systolic blood pressure ≥ 180 mm&#xD;
             Hg or diastolic blood pressure ≥ 110 mm Hg), uncontrolled cardiac arrhythmias, grade 3&#xD;
             or greater cardiac toxicity from prior chemotherapy&#xD;
&#xD;
          -  History of clinically significant drug or alcohol abuse&#xD;
&#xD;
          -  Unwillingness or inability to adhere to the requirements of the study&#xD;
&#xD;
          -  Concomitant therapy with corticosteroids (except as indicated in low dose for other&#xD;
             medical conditions such as inhaled steroid for asthma, or as premedication for&#xD;
             administration of certain medications or blood products and for treatment of infusion&#xD;
             reactions if needed)&#xD;
&#xD;
          -  Concomitant antineoplastic therapies including chemotherapy, radiotherapy, or&#xD;
             biological agents during the study&#xD;
&#xD;
          -  Any condition, including laboratory abnormalities, that in the opinion of the&#xD;
             Investigator places the subject at unacceptable risk if he or she are included in the&#xD;
             study&#xD;
&#xD;
          -  Pregnant or breast-feeding&#xD;
&#xD;
          -  Unwillingness to use an effective contraceptive method during the study and at least 3&#xD;
             months after administration of study drug - unless subject is naturally infertile.&#xD;
             (Acceptable contraceptive methods include oral or injectable contraceptives,&#xD;
             intrauterine devices (IUD), double-barrier method, contraceptive patch, surgical&#xD;
             sterilization, or condoms.)&#xD;
&#xD;
          -  Positive serum or urine pregnancy test&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kenneth C. Anderson, MD</last_name>
    <role>Study Director</role>
    <affiliation>Dana-Farber Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Emory University Winship Cancer Institute</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2013</verification_date>
  <study_first_submitted>July 24, 2008</study_first_submitted>
  <study_first_submitted_qc>July 24, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 28, 2008</study_first_posted>
  <last_update_submitted>July 16, 2013</last_update_submitted>
  <last_update_submitted_qc>July 16, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 18, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Multiple Myeloma</keyword>
  <keyword>Refractory</keyword>
  <keyword>Relapsed</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

